John P. Furey
John P. Furey
Imvax Chief Executive Officer

As Chief Executive Officer, John P. Furey leads the company’s development of its novel patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers. He also serves on the Imvax Board.

Most recently, John was Chief Operating Officer of Spark Therapeutics, Inc., where he led the successful US launch of LUXTURNA™, the first FDA-approved gene therapy for a genetic disease, and contributed to the build out of Spark as a fully integrated company. Prior to Spark, Mr. Furey served as Senior Vice President and Head of Global Operations at Baxalta, where he transformed the company’s global operations into a first-in-class supply chain network for rare diseases and led the 14,000-employee manufacturing, quality, engineering and process development organization. Earlier in his career, Mr. Furey initiated the restructuring and ultimate divestiture of Baxter International’s vaccines franchise to Pfizer. While at Pfizer, he transformed the China vaccine business into one of the company’s fastest growing units.

Mr. Furey also currently serves as non-executive director at Adaptimmune, a leader in T-cell therapy, and is an indepdent board member of Sensorion, a pioneering clinical-stage biopharmaceutical company developing therapies for the ear.

Mr. Furey earned an Executive MBA (Pharmaceutical Marketing) from St Joseph’s University, in Philadelphia, a Bachelor of Science with Honors from Trinity College, Dublin, and a Diploma in Environmental Health from the Dublin Institute of Technology.

David W. Andrews, MD
David W. Andrews, MD
Imvax Co-Founder, Chief Medical Officer

Anthony Alfred Chiurco, MD Professor of Neurological Surgery, Vice Chair of Clinical Services in the Department of Neurological Surgery, and Chief of the Division of Neuro-Oncology at Thomas Jefferson University Hospital.

As Chief Medical Officer at Imvax, Inc., Dr. Andrews communicates and engages with clinicians, researchers, and other key opinion leaders in the field regarding clinical development activities and potential product development. He develops strategic plans for the company’s product portfolio to ensure that development programs meet quality and safety standards required by patients, health care providers, and regulatory agencies. Dr. Andrews has a 30-year experience as an academic brain tumor neurosurgeon, completing residency at New York Presbyterian Cornell and a Fellowship at Memorial Sloan Kettering Cancer Center, both in New York, NY. As a junior attending neurosurgeon, he received a prestigious NIH Physician Scientist Award to study brain tumors and has devoted his career to find better treatment for glioblastoma. He currently resides at Thomas Jefferson University Hospital where he is Professor and Vice Chair of Clinical Services, Department of Neurological Surgery, and Chief of the Division of Neuro-Oncology.

Dr. Andrew’s raised nearly $7M dollars in philanthropy over a 20-year period to advance this promising immunotherapy platform for GBM, collaborating closely with his colleague Dr. Craig Hooper, a talented neuro-immunologist. He established the Brain Tumor Division at Thomas Jefferson University Hospital in 1995 and served as its Chief, expanding the Division to four neurosurgeons and two neuro-oncologists before stepping down to assume his role as a founder of Imvax, Inc. in 2015. Under his leadership, the Division became a national leader performing over 1,100 brain tumor treatments a year. His vision with Imvax, Inc. is to accelerate the development of this promising vaccine treatment.

Arthur W. Howe, IV, MBA
Arthur W. Howe, IV, MBA
Imvax Co-Founder, Chief Financial Officer

As Chief Financial Officer at Imvax, Inc., Art Howe is responsible for managing the company’s finances, including financial planning, management of financial risks, record-keeping, and financial reporting. He also serves as Chief Business Officer with responsibility for operations, strategy, and development. Mr. Howe has spent a career building transformative companies in media, technology and life sciences. He co-founded Imvax, Inc. in 2015 after launching, acquiring and building more than 50 media and technology companies. In 2005, Mr. Howe co-founded Verve, the leading platform for in mobile location-based technology. Prior to Verve, he served as a journalist, marketing executive and finance director at a large newspaper company, as well as CEO and president of several large groups of legacy newspapers.

Mr. Howe has received numerous journalism and public service recognitions, including the Pulitzer Prize, the Scripps Public Service Award, and the inaugural Ben Franklin Award for publishing excellence. Two alternative weeklies he ran, the Village Voice and the LA Weekly, won Pulitzer Prizes. Mr. Howe holds an undergraduate degree from the University of Pennsylvania and an MBA from the Wharton School at the University of Pennsylvania in Philadelphia, PA.

Catherine Kessler, MS
Catherine Kessler, MS
Chief Regulatory Officer

As Chief Regulatory Officer at Imvax, Inc., Catherine Kessler is responsible for oversight and management of regulatory affairs including nonclinical, clinical and CMC regulatory strategies and compliance within the company. Catherine has over 20 years of experience in the biotechnology and pharmaceutical industry, and has been working in regulatory affairs, quality assurance, regulatory compliance and operations activities since 2001. She has supported early and late-stage drug development in multiple therapeutic areas including oncology, inflammatory and cardiovascular diseases, and contraception and women’s health.

Ms. Kessler’s experience and knowledge of human blood therapeutics, biologics, and small molecules was gained while working in companies including Clinipace Clinical Research, Array BioPharma, Amgen, Aventis Behring, Centocor, and SmithKline Beecham Pharmaceuticals. She is well-versed in regulatory research and surveillance, developing regulatory paths to market for unique and complex investigational products, and engaging health authorities through the complex stages of clinical development. Ms. Kessler holds a BS in Biochemistry from the University of Delaware in Newark, DE and an MS in Quality Assurance and Regulatory Affairs from Temple University in Ambler, PA.

Mark Exley, PhD
Mark Exley, PhD
Chief Scientific Officer

Mark Exley, PhD, has been appointed as Chief Scientific Officer (CSO). Dr. Exley was previously Vice President, Cellular Immunology for AgenTus.

Dr. Exley’s areas of research have included natural and vaccine-supported immunity to cancers, immune responses to acute and chronic viral infections, suppression of graft-versus-host disease (a rare complication of bone marrow and stem cell transplants), obesity-associated diseases and other inflammations. Dr. Exley has published over 120 articles in scientific journals and has received numerous research awards and grants.

Prior to joining Imvax, Dr. Exley was on faculty at Harvard Medical School and at the University of Manchester, UK, where he retains honorary appointments, and was a scientist at Immulogic, Inc. He received his BS from Imperial College, London and his Ph.D. from the Institute of Cancer Research, London. He completed his post-doctoral fellowship at the Dana Farber Cancer Institute.